Clinical trials: Liver Diseases, Alcoholic
Nonalcoholic Fatty Liver Disease
A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-963272 in Participants With Nonalcoholic Fatty Liver Disease
The purpose of this study is to evaluate the safety, tolerability, and drug levels of BMS-963272 compared to placebo in participants with nonalcoholic fatty liver disease (NAFLD) and high probability of advanced fibrosis.
- Trial name
- NCT04766476
- Testing
- BMS-963272
- Where
- 19 sites in United States
- Volunteers
- 9 people
- Sponsor
- Bristol-Myers Squibb
Non-alcoholic Fatty Liver Disease (NAFLD)
Assessment of Hepatic Steatosis Using Dedicated Software Implemented on Ultrasound Devices
Non-alcoholic fatty liver disease (NAFLD) is currently the most common chronic liver disease, with an estimated prevalence of 5-30% in the general population and 55-80% in patients with type 2 diabetes.
- Trial name
- NCT07268937
- Testing
- CAP (Controlled Attenuation Parameter) module implemented on the Fibroscan machine.
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Metabolic Associated Fatty Liver Disease
Supplementation With Alpha-lipoic Acid and Silybum Marianum(LUDLEV®) for the Improvement of Fatty Liver Disease
This randomized, controlled, double-blind study evaluates the utility of alpha-lipoic acid and silybum marianum , versus placebo, in the treatment of metabolic associated fatty liver disease.
- Trial name
- NCT05913986
- Testing
- LUDLEV®300 mg/46.2 mg
- Where
- Mexico
- Volunteers
- 50 people
- Sponsor
- Saluz Investigación S. C.
Non-alcoholic Fatty Liver Disease, Obesity
The Influence of Autophagy on Fatty Liver
Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease worldwide. It is not known why only some obese subjects develop NAFLD.
- Trial name
- NCT01988441
- Where
- Taiwan
- Volunteers
- 800 people
- Sponsor
- Far Eastern Memorial Hospital
Liver Failure, Acute
Granulocyte Colony Stimulating Factor (G-CSF) in Acute Liver Failure and Alcoholic Hepatitis
Granulocyte colony stimulating factor in acute liver failure and alcoholic hepatitis
- Trial name
- G-CSF (NCT01341951)
- Testing
- Granulocyte colony stimulating factor
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Non-alcoholic Fatty Liver Disease, Metabolic Syndrome
Prebiotics in Patients With Non-alcoholic Liver Disease
The purpose of this present study is to evaluating whether prebiotics - ITF (Inulin/OFS 75/25) is effective in treating patients with non-alcoholic liver disease.
- Trial name
- NCT02642172
- Testing
- ITF (Inulin/OFS 75/25)
- Where
- Israel
- Volunteers
- 24 people
- Sponsor
- Kaplan Medical Center
Non Alcoholic Fatty Liver Disease
The Effect Of Omega-3 Fatty Acids on Non-alcoholic Fatty Liver Disease
There is preliminary evidence that Omega 3, a compound naturally found in fish oil, reduces the amount of fat stored in the liver and improves liver function.
- Trial name
- NCT01277237
- Testing
- Omacor, lactose tablet
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- University of Edinburgh
Non-Alcoholic Fatty Liver Disease
Efficacy of Phosphatidylcholine in NAFLD
This study evaluates efficacy of Phosphatidylcholine in addition to life style modification and patient health education by clinical Pharmacist in the Management of Non Alcoholic Fatty Liver NAFLD.
- Trial name
- NCT04411862
- Testing
- Phosphatidyl Choline, Lifestyle modification
- Volunteers
- 100 people
- Sponsor
- Nehal Abou Seada
Familial Partial Lipodystrophy, Nonalcoholic Steatohepatitis
CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy
The study investigators' aim is to determine the long term safety and efficacy of Metreleptin (Myalept,) in promoting amelioration of metabolic abnormalities in patients with all forms of partial lipodystrophy.
- Conditions
- Familial Partial Lipodystrophy, Nonalcoholic Steatohepatitis, NAFLD
- Trial name
- NCT02654977
- Testing
- Metreleptin
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Michigan
NAFLD (Nonalcoholic Fatty Liver Disease)
Evaluating the Safety and Efficacy of Rupatadine in the Treatment of Nonalcoholic Fatty Liver Disease Patients.
NAFLD is characterized by excessive hepatic fat accumulation without other recognized causes of increased fat content (e.g., alcohol, virus, drugs, and autoimmunity).
- Trial name
- NCT07900100
- Testing
- Rupatadin
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Tanta University
Pediatric Non-alcoholic Fatty Liver Disease
Comparison Between the Efficacy of Residential and Ambulatory Weight Loss Programs for Pediatric Non-alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) has become the most prevalent chronic liver disease worldwide, paralleling the obesity pandemic.
- Trial name
- NCT05309863
- Testing
- Lifestyle management
- Where
- 3 sites in Belgium
- Volunteers
- 850 people
- Sponsor
- University Hospital, Ghent
Nonalcoholic Fatty Liver
Weight, Energy, Lipids, and the Liver (WELL) Study
The research study is a parallel arm, randomized placebo-controlled clinical trial designed to assess changes in hepatic lipid accumulation, visceral adipose tissue and postprandial lipid, markers of inflammation and energy…
- Trial name
- NCT05199948
- Testing
- Soybean Oil Foods, Palm Oil Foods
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Ohio State University
Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis
A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)
This study is researching an experimental drug called ALN-CIDEB, also referred to as "study drug". The study is focused on participants with metabolic dysfunction-associated steatotic liver disease (MASLD) (Part A) and metabolic…
- Trial name
- NCT06836609
- Testing
- ALN-CIDEB
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 118 people
- Sponsor
- Regeneron Pharmaceuticals
Diabetes, Prediabetes
Meta-Analyses of the Effect of Plant Protein Versus Animal Protein on Cardiometabolic Risk
Vegetarian diets have been associated with a reduced risk of preventable diseases such as type 2 diabetes and cardiovascular disease. These effects may be mediated through direct or indirect pathways.
- Conditions
- Diabetes, Prediabetes, Metabolic Syndrome, Dysglycemia
- Trial name
- NCT02037321
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- John Sievenpiper
Non-alcoholic Steatohepatitis, Non-Alcoholic Fatty Liver Disease
Nutritional Cognitive Behavioral Therapy Feasibility Study in NAFLD and NASH
This single arm interventional cohort study is designed to explore the feasibility of using BT-NCBT-00x to improve liver fat, inflammation, and stiffness in patients diagnosed with NAFLD or NASH over a 3 month intervention.
- Conditions
- Non-alcoholic Steatohepatitis, Non-Alcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver
- Trial name
- NCT05357248
- Testing
- BT-NCBT-00X
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Better Therapeutics
Sarcopenia, Liver Cirrhosis
ELECTRICAL STIMULATION AND EXERCISE FOR MUSCLE LOSS IN CIRRHOSIS PATIENTS
Introduction: Sarcopenia, whether primary or secondary, substantially impacts the quality of life of patients post-hospital discharge. Compromised functional capacity can lead to a high prevalence of readmissions.
- Trial name
- E-SEEM (NCT07162636)
- Testing
- NMES+, NMES -
- Volunteers
- 112 people
- Sponsor
- Hospital Universitário Professor Edgard Santos
Alcohol Hepatitis
A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol Associated Hepatitis (Part 1)
A Phase 2 Clinical Trial Investigating the Safety and Efficacy of ADX-629 in Subjects with Moderate Alcohol Associated Hepatitis (Part 1)
- Trial name
- NCT06685692
- Testing
- ADX-629
- Where
- 6 sites in United States
- Volunteers
- 4 people
- Sponsor
- Aldeyra Therapeutics, Inc.
NASH, MASH
ALG-055009 in Non-cirrhotic Adults With MASH (HERALD)
This is a Phase 2a study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of oral (PO) daily (QD) doses of ALG-055009 (soft gelatin [softgel] capsule) for 12 weeks.
- Conditions
- NASH, MASH, Metabolic Dysfunction-Associated Steatohepatitis, Nonalcoholic Steatohepatitis
- Trial name
- HERALD (NCT06342947)
- Testing
- ALG-055009
- Where
- 40 sites in United States
- Volunteers
- 102 people
- Sponsor
- Aligos Therapeutics
Non-alcoholic Fatty Liver Disease (NAFLD)
Study to Evaluate the Effectiveness of Legalon®
This is a multinational, multicentre, prospective, non-interventional study (NIS) in non-alcoholic fatty liver disease (NAFLD) patients with concomitant metabolic syndrome treated with Legalon® combined with diet and exercise.
- Trial name
- NCT05051527
- Testing
- Legalon® 140 mg
- Where
- Thailand
- Volunteers
- 362 people
- Sponsor
- Mylan Inc.
Obesity and Type 2 Diabetes, NAFLD - Non-Alcoholic Fatty Liver Disease
OneSTOP (One-Stop Telehealth Obesity Program) for Multidisciplinary Weight Management and Related Comorbidities
The goal of this clinical trial is to learn if the use of a care model including teleconsults and the EMPOWER app can induce clinically significant weight loss and metabolic improvements in obese adults with diabetes and…
- Conditions
- Obesity and Type 2 Diabetes, NAFLD - Non-Alcoholic Fatty Liver Disease, Hypertension, Dyslipidaemia
- Trial name
- OneSTOP (NCT06890169)
- Testing
- OneSTOP program, Standard of care weight management program
- Where
- Singapore
- Volunteers
- 120 people
- Sponsor
- Changi General Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.